Anciens séminaires 2010-2018

Liste complète des anciens séminaires 2010-2014 :  angry     2015 :  pdf     2016 :  pdf     2017 :  pdf

Vendredi 14 décembre 2018, 14H

Sylvain Méloche


IRIC, Université de Montréal, Qc, Canada


"Identification and preclinical validation of new therapeutic targets in liver cancer."


Contact: marie-alix.poul@inserm.fr


Séminaire dans le cadre des enseignements du M2 Cancer Biology ?

Lundi 19 novembre 2018, 14h

Sylvie Mader


IRIC, Université de Montréal, Qc, Canada


"Targeting estrogen receptor signaling in breast cancer treatment: lessons from omics approaches and live cell biosensors"


Contact: marie-Alix.poul@inserm.fr


Séminaire dans le cadre des enseignements du M2 Cancer Biology 

Vendredi 26 octobre 2018, 4h

Chann Lagadec

INSERM U908, Cell Plasticity and Cancer, Université de Lille


“Reborn from fire, or how non-cancer stem cells reprogram as CSC under radiation-induced inflammatory chemokines stimulation”



Cancer stem cell (CSC) identification in solid and hematologic tumors has paved the way to many fundamental and translational studies. However, recent studies have depicted the presence of cancer stem cell plasticity. Indeed, differentiated breast cancer cells (non-CSCs) can generate iCSCs (induced CSCs) in response to various stimuli. Nevertheless, reprogramming mechanisms remain unknown, and strategies to reduce the reprogramming of non-CSCs into iCSCs might prevent treatment-resilient cancer cells driving recurrences. We demonstrated, for the first time, that chemokines are involved in reprogramming and can be used to target radiation-induced CSC enrichment. In combination with radiation treatment, inhibition of these chemokines allows increased survival of mice in xenograft model. We also demonstrated that the expression of chemokines and their receptors is associated with CSC profiles in tumor patients. More interestingly, expression of specific chemokines or their receptors could be useful as prediction markers. We are actually investigating intracellular mechanisms driving anti-cancer treatments-induced reprogramming. Also, we are developing the first animal transgenic model to track and distinguish CSCs from iCSCs, and so to study in vivo reprogramming.


Mercredi 10 Octobre 2018, 14h

Somadri Ghosh 


Université Libre de Bruxelles


"A role of SHIP2 in metastasis of breast cancer“


Contact: andrei.turtoi@inserm.fr

Vendredi 21 septembre 2018, 14h

Eric Soler


IGMM, CNRS, Université de Montpellier


"Chromatin looping as a regulator of normal and pathological erythropoiesis"


contact: eric.julien@inserm.fr

Vendredi 7 septembre 2018, 14h

Joffrey Pelletier


IDIBELL, Barcelone


“Targeting GMP synthesis reveals a hierarchy of p53-cell cycle checkpoints in CRCs”


contact: laurent.lecam@inserm.fr

Vendredi 13 Juillet 2018, 14H

Franck Vandemoere, 


IGF, CNRS UMR5203, INSERM U1191, Montpellier


"Regulation by phosphorylation of two GPCRs targeted by antipsychotics"


Contact: pierre.martineau@inserm.fr

Vendredi 6 Juillet 2018, 14h00

Fanny Jaulin, 


INSERM-U981 Institut Gustave Roussy, Villejuif.


"Collective epithelial-based metastases in colorectal carcinoma patients"


As a critical step in cancer progression and a challenge to patient treatment, tumour cell dissemination has been the subject of intense investigation across a range of model systems, in vitro and in animals. These studies have led to the assumption that the fatal progression of carcinoma is associated with a loss of epithelial architecture and polarity1-3 as single tumour cells escape from the primary tumour to reach secondary sites4,5. However, these studies have been performed using experimental model systems and the mechanisms driving metastatic spread in cancer patients remain under-investigated. Here, we collected and monitored over 50 patient specimens ex vivo to investigate the cell biology of colorectal cancer (CRC) metastasis as it spreads to the peritoneum. This reveals a new mode of cancer dissemination. Large clusters of cancer epithelial cells displaying an inverted apico-basolateral polarity, which we term Tumour Spheres with Inverted Polarity (TSIPs), were observed throughout the process of tumour dissemination. We show that TSIPs form and propagate through the collective apical budding of hyper-methylated neoplastic tissues. Despite their inverted topology, TSIPs collectively invade extracellular matrices, paired patients¹ peritoneum explants and initiate metastases in mice xenograft models. Further, the presence of TSIPs in peritoneal effusions correlates with metastases burden and adverse patient prognosis. Thus, despite their having a robust epithelial architecture, TSIPs appear to drive the peritoneal dissemination of CRC, as well as other primary cancers, such as breast carcinoma.  By applying cell biological methods to live primary cancer specimens, we provide an alternative conception of cancer dissemination that goes against the prevailing consensus and could not be anticipated from experimental model systems.


Contact: charles.theillet@inserm.fr

Vendredi 29 Juin 2018, 14h00

Daniel Fisher


IGMM, CNRS Montpellier


"Not just a proliferation marker: Ki-67 promotes carcinogenesis by organising the nucleus to promote cellular plasticity"


Contact: charles.theillet@inserm.fr

Vendredi 22 Juin 2018, 14h00

Jérôme Déjardin


IGH, CNRS, Montpellier 


"Atypical heterochromatin stimulates alternative lengthening of telomeres"


Contact: claude.sardet@inserm.fr

Mercredi 20 Juin 2018, 14h00

Giulio Preta


Life Science Center, Vilnius University, Lithuania


'Targeting lipid rafts as a strategy against infection and cancer"


Short summary of the work: 

Lipid rafts are membrane micro-domains that are enriched in cholesterol, sphingomyelin, sphingolipids and phospholipids. Their importance for living cells is underlined by their involvement in many processes including bacterial and viral entry, cardiovascular and prion diseases as well as cancer. Targeting lipid rafts is emerging as an innovative strategy to limit bacterial or viral infection and to increase the sensitivity to apoptosis of different types of tumours. Behind well-known cholesterol depleting agents (cyclodextrin) new compounds involved in cholesterol homeostasis were recently discovered. These potential drug candidates are capable to modify the lipid rafts composition and to alter the signalling platform associated with them.  Multiple technologies including confocal microscopy to visualize lipid rafts, viability assays to determine the toxic effect of compounds on the cells, offer the opportunity to study in details the changes induced by this new class of cholesterol-targeting agents.

Mardi 12 Juin 2018, 14h00

Julien Faget


ISREC/EPFL, Lausanne, Suisse


"Learning from models of immunotherapy resistant lung cancer"



Vendredi 8 Juin 2018, 14h00

Roberto Ronca


Department of Molecular and Translational Medicine, University of Brescia

"Stromal delivery of long Pentraxin-3 impairs FGF/FGFR-dependent tumor growth and metastasis"


Summary of the work: 

The fibroblast growth factor (FGF)/FGF receptor (FGFR) system plays a crucial role in cancer by affecting tumor growth, angiogenesis, drug resistance and escape from anti-angiogenic anti-vascular endothelial growth factor therapy. The soluble pattern recognition receptor long-pentraxin 3 (PTX3) acts as a multi-FGF antagonist. In a recent study we demonstrated that local and systemic delivery of human PTX3 in transgenic mice driven by the endothelial specific Tie2 promoter inhibits tumor growth, angiogenesis and metastasis in heterotopic, orthotopic and autochthonous FGF-dependent tumor models. Moreover, NMR data and pharmacophore modeling of the interaction of a minimal PTX3-derived FGF-binding pentapeptide with FGF2 were used for the identification of the first small molecule chemical (NSC12) which acts as an orally active extracellular FGF trap with significant implications in cancer therapy. We are currently characterizing the role of PTX3 expression in different types of solid and hematological tumors.



Vendredi 18 Mai 2018, 14h00

Han Li


Cellular Plasticity and Disease Modelling Group, Institut Pasteur, Paris


"Cellular plasticity in cancer and ageing"


Webmore information


Contact: antonio.maraver@inserm.fr

Vendredi 27 Avril 2018, 14h00

William Ritchie


Head of Artificial Intelligence and Gene Regulation, IGH, Montpellier


“Artificial Intelligence empowers transcriptomics but will ultimately cause its demise"


The seminar in short:

In my talk, I will show how simple information theory concepts such as entropy and information content allow scientists to better understand gene regulation in numerous types of disease. I will then demonstrate that recent advances in artificial intelligence approaches such as genetic programming and neural nets may be so powerful that they abrogate our need to understand these functions at all. Recent research in my team will show how AI allows us to explore sequencing data from cancer samples with no a priori and is more powerful than current approaches for classifying and predicting outcomes.


Contact: charles.theillet@inserm.fr

Vendredi 20 Avril 2018, 14h00

Mickael Ploquin,


10x Genomics


"Single cell transcriptomics and proteomics"




Résumé de la présentation :  High-throughput, single-cell expression measurements enable discovery of gene expression dynamics for profiling individual cell types. The Chromium Single Cell Controller which is a dedicated instrument for single cell applications and features a simple and comprehensive workflow, enabling users to quickly and easily prepare single cell sequencing libraries in less than one workday.


With the unique ability to interrogate hundreds to millions of cells, the Single Cell Chromium Controller supports a variety of applications, including the existing Chromium™ Single Cell 3’ Solution, as well as a future product featuring to perform full-length sequencing of V(D)J segments from single B or T cells. The system is accompanied by Chromium Single Cell 3’ Reagent Kits with advanced chemistry and microfluidics consumables based on GemCode™ Technology and features full compatibility with the Illumina® HiSeq® 4000 and other HiSeq®, NovaSeq®, NextSeq® and MiSeq® sequencers.

Jeudi 29 Mars 2018, 14h00

Max Chaffanet


Département d’Oncologie Moléculaire Institut Paoli Calmettes, Marseille


“Profilage oncogénomique des cancers avancés dans les essais PANDORA et PERMED à l’IPC"


Contact: charles.theillet@inserm.fr

Vendredi 9 Février 2018, 14h00

Sylvain Lehmann et Brigitte Couette


Projet IBDLR (Initiative Biomarqueurs et Diagnostic en Languedoc-Roussillon), BioCampus, Montpellier


"Présentation de l’ (IBDLR) : Actions et Appel à candidature "Labellisation de projets Biomarqueurs" 


Contact: charles.theillet@inserm.fr


Bref résuméL’objet de cette présentation, qui s’inscrit dans une démarche systématique auprès des différents Instituts/laboratoires, est de faire connaître notre initiative qui a pour vocation de faciliter l’émergence et la validation de nouveaux Biomarqueurs en accompagnant les chercheurs sur le chemin de la valorisation économique de leurs activités de recherche.

IBDLR sert d’interface entre les laboratoires de recherche et les structures de valorisation : https://www.polebiosante-rabelais.fr/polerabelais/projets-structurants/ibdlr

Ses missions :
  • Faciliter l’émergence et la validation de nouveaux Biomarqueurs
  • Apporter son expertise pour accompagner les projets vers un niveau de maturité technologique pour une prise en charge par les acteurs régionaux de la valorisation
  • Décerner un label pour les projets ayant des perspectives pouvant intéresser des industriels
  • Financer des équipements performants pour la validation des Biomarqueurs (CPER-IBDLR)
  • Organiser des évènements autour des Biomarqueurs

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés